^
Association details:
| Biomarker: | TP53 mutation + Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/03/2022
Excerpt:
SUGGESTED TREATMENT REGIMENS...CLL/SLL with del(17p)/TP53 mutation...Preferred regimens...Venetoclax + rituximab
Source:
Title:
IMPACT OF TP53-MUTATED CLONE SIZE ON OUTCOME OF RELAPSED/REFRACTORY (R/R) CLL PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB WITHIN THE PHASE 3 MURANO STUDY
Published date:
05/17/2018
Excerpt:
Patients with both del(17p) and TP53 mutations, indicative of loss of TP53 on both alleles, had inferior outcomes to pts with either del(17p) or TP53 mutation alone, with BR. Importantly, PFS was superior for VenR vs BR across subgroups with del(17p) and/or TP53 mutations including high and low clone size.
